Psyence Biomedical Ltd.
PBM
Rank in Stocks
#30582
Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines... Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.
Share Price
$3.15
Last synced: 2026-11-13
Market Cap
$4.67M
Change (1 day)
1.94%
Change (1 year)
-81.18%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Psyence Biomedical Ltd. (PBM)
Category
Healthcare
EPS for Psyence Biomedical Ltd. (PBM)
EPS as of September 2025 TTM: $-0.51
According to Psyence Biomedical Ltd.'s latest financial reports, its current EPS (TTM) is $-0.51. At the end of 2025 the company had an EPS of $1.78, an increase over its 2024 EPS of $-7.85.
EPS history for Psyence Biomedical Ltd. from 2022 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.51 | -128.65% |
| 2025 | $1.78 | -122.68% |
| 2024 | $-7.85 | 1,559.27% |
| 2023 | $-0.47 | -336.55% |
| 2022 | $0.20 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $-0.89 | 74.51% |
US
|
|
| $15.66 | -3,170.59% |
US
|
|
| $-7.07 | 1,286.27% |
US
|
|
| $-5.29 | 937.25% |
AU
|
|
| $12.73 | -2,596.51% |
BE
|
Questions about Psyence Biomedical Ltd.'s earnings per share (EPS)
What is Psyence Biomedical Ltd.'s earnings per share (EPS)?
Psyence Biomedical Ltd.'s earnings per share (EPS) over the last twelve months is $-0.51, as of Sep 2025.
What was Psyence Biomedical Ltd.'s earnings per share (EPS) in 2025?
In 2025, Psyence Biomedical Ltd.'s earnings per share (EPS) was $1.78, compared with $-7.85 in 2024.
How has Psyence Biomedical Ltd.'s earnings per share (EPS) changed since 2022?
From 2022 to 2025, Psyence Biomedical Ltd.'s earnings per share (EPS) went from $0.20 to $1.78, an average growth of 107.24% a year.
How does Psyence Biomedical Ltd.'s earnings per share (EPS) compare with similar companies?
Psyence Biomedical Ltd.'s earnings per share (EPS) ($-0.51) is higher than that of 3 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.